Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

36.19
+0.14000.39%
Post-market: 36.190.00000.00%16:15 EDT
Volume:3.52M
Turnover:127.24M
Market Cap:42.16B
PE:60.32
High:36.55
Open:36.52
Low:35.85
Close:36.05
52wk High:38.37
52wk Low:18.14
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.74
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.44
PE(LYR):29.91

Loading ...

Teva Pharmaceutical Beats First-Quarter Profit Estimates On Branded Drugs Demand

Reuters
·
Apr 29

GUIDANCE: (TEVA) Teva Pharmaceutical Industries Expects 2026 Non-GAAP EPS Range $1.91 - 2.11

MT Newswires Live
·
Apr 29

Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Benzinga Earnings
·
Apr 29

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Dow Jones
·
Apr 29

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors

Simply Wall St.
·
Apr 28

Teva Pharmaceutical Industries Ltd expected to post earnings of 46 cents a share - Earnings Preview

Reuters
·
Apr 27

Earning Preview: Teva Pharmaceutical this quarter’s revenue is expected to decrease by 4.49%, and institutional views are bullish

Earnings Agent
·
Apr 23

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 21

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch

Simply Wall St.
·
Apr 19

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Apr 16

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Apr 09

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential

Simply Wall St.
·
Mar 31